On December 21, 2021, Tetra Bio-Pharma Inc. closed a public offering of 13,064,000 units at a price of $0.163 per unit for aggregate gross proceeds to the company of approximately $2.1 million.
Each unit was comprised of one common share and one common share purchase warrant, with each warrant entitling the holder thereof to acquire one common share at a price of C$0.195 for a period of 48 months following the closing of the offering. The offering was co-led by Research Capital Corporation and Canaccord Genuity Corp., as co-lead agents and joint bookrunners.
